jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Elbow mass - Medium Biopsy 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Tissue biopsy of elbow swelling.

₹370₹529

30% OFF

Elbow Mass - Medium Biopsy 1-3 cm

  • Why is it done?
    • To obtain tissue samples from a 1-3 cm mass or lesion located in the elbow region for histopathological examination and diagnosis
    • To determine the nature of the elbow mass, including whether it is benign or malignant
    • To identify specific pathological conditions such as lipomas, ganglion cysts, synovial tumors, or soft tissue sarcomas
    • To guide treatment planning and determine appropriate surgical or medical management
    • Performed when clinical examination, imaging (ultrasound or MRI), and physical findings are inconclusive regarding the nature of the mass
    • Used for masses of intermediate size that require tissue confirmation before definitive surgical intervention
  • Normal Range
    • Normal/Benign Finding: Histopathology shows normal or benign tissue characteristics with clearly differentiated cellular architecture and no evidence of malignancy
    • Benign masses typically include: lipomas (mature fat cells), ganglion cysts (myxoid material), fibromas, or other non-cancerous soft tissue lesions
    • Abnormal Finding: Presence of malignant cells, atypical cellular features, increased mitotic activity, or diagnostic markers consistent with sarcoma or other malignancy
    • Units of Measurement: Histological findings reported as morphological descriptions with cellular grade (Grade 1-3 for sarcomas) and tumor classification
    • Interpretation basis: Binary classification of benign vs. malignant with additional characterization of tumor type, grade, and stage when applicable
  • Interpretation
    • Benign Diagnosis (Lipoma, Ganglion Cyst, Fibroma): Indicates no malignancy present; conservative management or simple surgical excision may be appropriate
    • Atypical/Borderline Findings: May indicate atypical lipomatous tumor (ALT) or other intermediate lesions; repeat biopsy, closer imaging follow-up, or surgical consultation recommended
    • Low-Grade Malignancy: Shows cellular atypia with low mitotic rate; requires wide surgical excision and potential adjuvant therapy planning
    • High-Grade Malignancy (Sarcoma): Indicates aggressive malignancy with high mitotic rate and cellular pleomorphism; requires urgent oncologic consultation, staging studies, and multimodal treatment
    • Factors Affecting Interpretation: Specimen adequacy, biopsy location within lesion (core sampling may miss heterogeneous areas), prior imaging findings, and patient demographics
    • Immunohistochemical Markers: May be used to classify specific tumor types (synovial sarcoma, clear cell sarcoma, etc.) and guide prognosis and treatment
  • Associated Organs
    • Primary Organ System: Soft tissue structures of the elbow including skin, subcutaneous tissue, muscles, tendons, ligaments, and joint capsule
    • Benign Conditions Diagnosed: Lipomas, ganglion cysts, fibromas, hemangiomas, osteochondromas, synovitis, and inflammatory lesions
    • Malignant Conditions Diagnosed: Synovial sarcoma, liposarcoma, clear cell sarcoma, rhabdomyosarcoma, fibrosarcoma, and other soft tissue sarcomas
    • Associated Complications of Malignancy: Local invasion of surrounding structures, regional lymph node involvement, distant metastasis (lungs, bone), functional impairment, and potential limb-threatening progression
    • Biopsy-Related Risks: Infection, bleeding, hematoma formation, nerve or blood vessel injury, temporary pain/swelling, and rare tumor cell seeding along biopsy tract
  • Follow-up Tests
    • If Benign Diagnosis: Clinical follow-up as needed; repeat imaging only if mass changes clinically; no routine surveillance required
    • If Malignancy Confirmed: MRI of elbow and upper arm for precise lesion characterization and surgical planning; CT chest/abdomen/pelvis for metastatic staging
    • Additional Staging Studies: PET-CT for high-grade sarcomas; bone scan if bone involvement suspected; regional lymph node ultrasound or imaging
    • Oncologic Consultation: Surgical oncology, medical oncology, and radiation oncology as appropriate for treatment planning
    • Genetic/Molecular Testing: FISH for synovial sarcoma (t(X;18) translocation) or other specific chromosomal abnormalities based on histologic diagnosis
    • If Atypical/Borderline Results: Repeat biopsy (excisional if core biopsy performed initially); close imaging follow-up at 3-6 months; surgical consultation for potential excision
    • Post-Treatment Monitoring: Serial imaging (MRI/CT) every 3-6 months initially, then annually; clinical examination at each follow-up; screening for recurrence and metastatic disease
  • Fasting Required?
    • Fasting Required: No fasting is required for this biopsy procedure
    • Pre-Procedure Instructions: Patient may eat and drink normally; however, if sedation or general anesthesia is used, NPO (nothing by mouth) 6-8 hours before procedure required
    • Medications to Hold: Anticoagulants (warfarin, apixaban, dabigatran) should be held 3-5 days before procedure; aspirin and NSAIDs discontinued 3-7 days prior; antiplatelet agents per physician discretion
    • Skin Preparation: Bathe or shower with soap and water the night before; may use surgical scrub (chlorhexidine or povidone-iodine) on biopsy site morning of procedure
    • Clothing and Jewelry: Wear loose-fitting, comfortable clothing to allow easy access to elbow; remove jewelry, watches, and metal items from the arms
    • Lab Work: CBC, PT/INR, PTT may be ordered 24-48 hours before procedure to assess clotting function
    • Transportation: Arrange for a responsible adult to drive if sedation or anesthesia is planned; patient should not operate machinery for 24 hours after procedure

How our test process works!

customers
customers